Vol 21, No 3 (2017)
Editorial
Published online: 2017-09-29
Leki złożone w terapii nadciśnienia tętniczego w Polsce Stanowisko Ekspertów Polskiego Towarzystwa Nadciśnienia Tętniczego oraz Sekcji Farmakoterapii Sercowo-Naczyniowej Polskiego Towarzystwa Kardiologicznego
DOI: 10.5603/AH.2017.0014
Arterial Hypertension 2017;21(3):105-115.
Abstract
Nadciśnienie tętnicze jest podstawowym modyfikowalnym czynnikiem ryzyka chorób sercowo-naczyniowych: choroby niedokrwiennej serca, udaru mózgu, niewydolności serca i choroby niedokrwiennej tętnic kończyn dolnych, a także najistotniejszą epidemiologicznie przyczyną zgonów na świecie. Jednocześnie częstość występowania nadciśnienia tętniczego w Polsce stale rośnie — według badania NATPOL z 2002 roku — dotyczyła 29% populacji dorosłych Polaków [1], w powtórnym badaniu NATPOL 2011 wzrosła do 32% [2], a w badaniu WOBASZ II w 2014 roku wynosiła już 43% [3].
Keywords: leki złożonenadciśnienie tętniczePTNT
References
- Zdrojewski T, Bandosz P, Szpakowski P. Ocena wybranych problemów dotyczących rozpowszechnienia i terapii nadciśnienia tętniczego w Polsce na podstawie badania NATPOL-PLUS. W Postępy w nefrologii i nadciśnieniu tętniczym. Vol II. Medycyna Praktyczna, Kraków 2002: 11–15.
- www.natpol.pl.
- Niklas A, Tykarski A. Dane z badania WOBASZ 2017.
- Widecka K, Grodzicki T, Narkiewicz K, et al. Zasady postępowania w nadciśnieniu tętniczym-2011 rok. Wytyczne Polskiego Towarzystwa Nadciśnienia Tętniczego. Nadciśnienie Tętnicze. 2011; 15(2): 55–82.
- Tykarski A, Narkiewicz K, Gaciong Z, et al. Zasady postępowania w nadciśnieniu tętniczym - 2015 rok. Wytyczne Polskiego Towarzystwa Nadciśnienia Tętniczego. Nadciśnienie Tętnicze w Praktyce. 2015; 1(1): 1–70.
- Gaciong Z, Narkiewicz K, Tykarski A, et al. Miejsce gotowych połączeń lekowych w terapii nadciśnienia tętniczego – stanowisko ekspertów. Nadciśnienie Tętnicze. 2009; 13: 363–370.
- Wożakowska-Kapłon B, Filipiak K, Czarnecka D, et al. Miejsce leków złożonych w terapii nadciśnienia tętniczego — aktualne problemy w Polsce Stanowisko Ekspertów Polskiego Towarzystwa Nadciśnienia Tętniczego i Sekcji Farmakoterapii Sercowo-Naczyniowej Polskiego Towarzystwa Kardiologicznego. Kardiologia Polska. 2013; 71(4): 433–438.
- Wald DS, Law M, Morris JK, et al. Combination therapy versus monotherapy in reducing blood pressure: meta-analysis on 11,000 participants from 42 trials. Am J Med. 2009; 122(3): 290–300.
- Weber M, Julius S, Kjeldsen S, et al. Blood pressure dependent and independent effects of antihypertensive treatment on clinical events in the VALUE Trial. Lancet. 2004; 363(9426): 2049–2051.
- Mancia G, Fagard R, Narkiewicz K, et al. 2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J. 2013; 34(28): 2159–2219.
- Gupta AK, Arshad S, Poulter NR. Compliance, safety, and effectiveness of fixed-dose combinations of antihypertensive agents: a meta-analysis. Hypertension. 2010; 55(2): 399–407.
- Waeber B, Burnier M, Brunner HR. Compliance with antihypertensive therapy. Clin Exp Hypertens. 1999; 21(5-6): 973–985.
- Wan X, Ma P, Zhang X. A promising choice in hypertension treatment: Fixed-dose combinations. Asian J Pharmac Sciences. 2014; 9(1): 1–7.
- Mallat SG, Tanios BY, Itani HS, et al. Free versus Fixed Combination Antihypertensive Therapy for Essential Arterial Hypertension: A Systematic Review and Meta-Analysis. PLoS One. 2016; 11(8): e0161285.
- Corrao G, Nicotra F, Parodi A, et al. Cardiovascular protection by initial and subsequent combination of antihypertensive drugs in daily life practice. Hypertension. 2011; 58(4): 566–572.
- Jamerson K, Weber M, Bakris G, et al. Benazepril plus Amlodipine or Hydrochlorothiazide for Hypertension in High-Risk Patients. N Engl J Med. 2008; 359(23): 2417–2428.
- Mancia G, Backer GDe, Dominiczak A, et al. 2007 Guidelines for the Management of Arterial Hypertension. J Hypertens. 2007; 25(6): 1105–1187.
- Feldman RD, Zou GY, Vandervoort MK, et al. A simplified approach to the treatment of uncomplicated hypertension: a cluster randomized, controlled trial. Hypertension. 2009; 53(4): 646–653.
- Mourad JJ, Waeber B, Zannad F, et al. Comparison of different therapeutic strategies in hypertension: a low-dose combination of perindopril/indapamide versus a sequential monotherapy or a stepped-care approach. J Hypertens. 2004; 12(22): 2379–2386.
- Laurent S, Parati G, Chazova I, et al. Randomized evaluation of a novel, fixed-dose combination of perindopril 3.5 mg/amlodipine 2.5 mg as a first-step treatment in hypertension. J Hypertens. 2015; 33(3): 653–61; discussion 662.
- Mancia G, Asmar R, Amodeo C, et al. Comparison of single-pill strategies first line in hypertension: perindopril/amlodipine versus valsartan/amlodipine. J Hypertens. 2015; 33(2): 401–411.
- Tykarski A. Doniesienie własne.
- van Vark LC, Bertrand M, Akkerhuis KM, et al. Angiotensin-converting enzyme inhibitors reduce mortality in hypertension: a meta-analysis of randomized clinical trials of renin-angiotensin-aldosterone system inhibitors involving 158,998 patients. Eur Heart J. 2012; 33(16): 2088–2097.
- Cheng J, Zhang W, Zhang X, et al. Effect of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers on all-cause mortality, cardiovascular deaths, and cardiovascular events in patients with diabetes mellitus: a meta-analysis. JAMA Intern Med. 2014; 174(5): 773–785.
- Savarese G, Costanzo P, Cleland JG, et al. A meta-analysis reporting effects of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in patients without heart failure. J Am Coll Cardiol. 2013; 61(2): 131–142.
- Dahlöf B, Sever PS, Poulter NR, et al. ASCOT Investigators. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet. 2005; 366(9489): 895–906.
- Williams B, O'Rourke M. Anglo-Scandinavian Cardiac Outcomes Trial. The Conduit Artery Functional Endpoint (CAFE) study in ASCOT. J Hum Hypertens. 2001; 15 Suppl 1: S69–S73.
- Bahl VK, Jadhav UM, Thacker HP. Management of hypertension with the fixed combination of perindopril and amlodipine in daily clinical practice: results from the STRONG prospective, observational, multicenter study. Am J Cardiovasc Drugs. 2009; 9(3): 135–142.
- Miranda RD, Mion D, Rocha JC, et al. An 18-week, prospective, randomized, double-blind, multicenter study of amlodipine/ramipril combination versus amlodipine monotherapy in the treatment of hypertension: the assessment of combination therapy of amlodipine/ramipril (ATAR) study. Clin Ther. 2008; 30(9): 1618–1628.
- Farsang C, Abraham G, Kovacs P, et al. The effictivity and safety of Amlodipin-Lisinopril Fix-combination in patients with ESSential hypertension (ALFESS Study). Hypertonia es Nefrologia. 2009; 13: 81–87.
- Farsang C. HAMLET Trial Investigation: Advantages of lisinopril amlodypine fixed combination therapy in hypertension. A comparative study of the efficacy and tolerability of amlodipine 5 mg and lisinopril 10 mg administered separately and in combination in hypertension. Hypertonia es Nephrologia. 2004; 8: 72–78.
- Mancia G, Omboni S, Chazova I, et al. FELT Study Group. Effects of the lercanidipine-enalapril combination vs. the corresponding monotherapies on home blood pressure in hypertension: evidence from a large database. J Hypertens. 2016; 34(1): 139–148.
- Patel A. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet. 2007; 370(9590): 829–840.
- Beckett NS, Peters R, Fletcher AE, et al. HYVET Study Group. Treatment of hypertension in patients 80 years of age or older. N Engl J Med. 2008; 358(18): 1887–1898.
- PROGRESS Collaborative Group. Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6105 individuals with previous stroke or transient ischaemic attack. Lancet. 2001; 358(9287): 1033–1041.
- Dahlöf B, Devereux R, Kjeldsen S, et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet. 2002; 359(9311): 995–1003.
- Julius S, Weber MA, Kjeldsen SE, et al. VALUE trial group. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet. 2004; 363(9426): 2022–2031.
- Allemann Y, Fraile B, Lambert M, et al. Efficacy of the combination of amlodipine and valsartan in patients with hypertension uncontrolled with previous monotherapy: the Exforge in Failure after Single Therapy (EX-FAST) study. J Clin Hypertens (Greenwich). 2008; 10(3): 185–194.
- Littlejohn TW, Majul CR, Olvera R, et al. study investigators. Telmisartan plus amlodipine in patients with moderate or severe hypertension: results from a subgroup analysis of a randomized, placebo-controlled, parallel-group, 4 x 4 factorial study. Postgrad Med. 2009; 121(2): 5–14.
- Chalmers J, et al. ADVANCE Collaborative Group. J Hypertens. 2013; 31(Suppl A): e110.
- Tóth K. PIANIST Investigators. Antihypertensive efficacy of triple combination perindopril/indapamide plus amlodipine in high-risk hypertensives: results of the PIANIST study (Perindopril-Indapamide plus AmlodipiNe in high rISk hyperTensive patients). Am J Cardiovasc Drugs. 2014; 14(2): 137–145.
- Niewada M, Filipiak KJ, Barszcz E, et al. Dobór optymalnego połączenia beta-adrenolityk–antagonista wapnia w praktyce leczenia osób ze współistniejącą chorobą wieńcową i nadciśnieniem tętniczym — analiza wyników badania ankietowego BETAMLO. Nadciśnienie Tętnicze. 2012; 16(6): 364–373.
- Rana R, Patil A. Efficacy and Safety of Bisoprolol plus Amlodipine Fixed Dose Combination in Essential Hypertension. Indian Pract. 2008; 61: 225–234.
- Jadhav U, Hiremath J, Namjoshi DJ, et al. Blood pressure control with a single-pill combination of indapamide sustained-release and amlodipine in patients with hypertension: the EFFICIENT study. PLoS One. 2014; 9(4): e92955.
- Bertrand ME, Ferrari R, Remme WJ, et al. Perindopril and β-blocker for the prevention of cardiac events and mortality in stable coronary artery disease patients: A EUropean trial on Reduction Of cardiac events with Perindopril in stable coronary Artery disease (EUROPA) subanalysis. Am Heart J. 2015; 170(6): 1092–1098.
- Prejbisz A, Klocek M, Gąsowski J, et al. Factors associated with resistant hypertension in a large cohort of hypertensive patients: the Pol-Fokus study. Pol Arch Med Wewn. 2015; 125(4): 249–259.
- Ridker PM, Danielson E, Fonseca FA, et al. for the UPITER Study Group. Rosuvastatin to prevent vascular eventsin men and women with elevated C-reactive protein. N Engl J Med. 2008; 359: 2195–2207.
- Sever PS, Dahlöf B, Poulter NR, et al. ASCOT Investigators, ASCOT investigators. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial--Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet. 2003; 361(9364): 1149–1158.
- McMurray JJ, Holman RR, Haffner SM, et al. NAVIGATOR Study Group. Effect of valsartan on the incidence of diabetes and cardiovascular events. N Engl J Med. 2010; 362(16): 1477–1490.
- Galindo-Ocaña J, Bernabeu-Wittel M, Formiga F, et al. PROFUND Project researchers. Effects of renin-angiotensin blockers/inhibitors and statins on mortality and functional impairment in polypathological patients. Eur J Intern Med. 2012; 23(2): 179–184.